e-therapeutics plc (LON:ETX – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 10.26 ($0.14) and traded as low as GBX 9 ($0.12). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares.
e-therapeutics Trading Down 6.7 %
The business’s 50-day moving average is GBX 9 and its two-hundred day moving average is GBX 10.22. The company has a debt-to-equity ratio of 0.33, a quick ratio of 20.13 and a current ratio of 22.20. The stock has a market capitalization of £52.59 million, a PE ratio of -450.00 and a beta of 0.46.
About e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Further Reading
- Five stocks we like better than e-therapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- When Is the Best Time to Invest in Mutual Funds?
- Consumer Discretionary Stocks Explained
- Is NVIDIA Stock in a Correction or Consolidation?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.